Background
The licensed lopinavir/r paediatric total daily dose is 460 mg/m2 without, and 600 mg/m2 with concurrent NNRTIs. The 460 mg/m2 dose without NNRTIs was chosen in preference to 600 mg/m2 in a post-hoc drug-interaction analysis [1] . Excellent VL suppression was also reported (79% <400 c/ml at 48 wks) but was based on the higher 600 mg/m2 dose. Thus, some paediatricians prefer this higher dose regardless of concomitant NNRTI therapy.
Methods
We calculated lopinavir/r doses (mg/m2) prescribed without NNRTIs in the UK/Irish CHIPS cohort from 2000-2007, every time height/weight was measured. We investigated predictors of current dose, including sex; VL and CD4% at the previous visit, current age, CDC stage, height/weight-for-age, calendar year, formulation, frequency and previous PI using mixed models with random effects for child and centre. We considered whether current lopinavir/r dose predicted the next VL being <400 c/ ml using binomial mixed models.
Summary of results
311/1,336 (25%) children in CHIPS had ever taken lopinavir/r without NNRTIs, total 654 child-years. Median age at lopinavir/r initiation was 9.0 years (IQR 5.1-12.1). 684 doses were recorded in 299/311 children: 52% were syrup, 38% capsules and 10% tablets, with only 3% once (rather than twice) daily. Dose/m2 could be estimated 2,748 times in 278 children: few (6%) were >10% below the 460 mg/m2 target, and few (9%) >10% above the 600 mg/m2 target, with most >410-<530 mg/m2 (46%) or >530-<660 mg/m2 (39%). In a multivariable model, doses were 17 mg/m2 [95%CI 0-34] higher in children who had prior AIDS, 2 mg/m2 [0-3] higher for every log10 higher VL at the previous visit, 48 mg/m2 [38-58] higher with capsules/tablets vs. syrups, 22 mg/m2 [4-40] higher with twice-vs. once-daily dosing, 19 mg/m2 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and 10 mg/m2 [6-14] higher for every one unit lower current weight-and height-for-age, respectively, and 9 mg/m2 [5-14] higher for every year younger under 10 (p < 0.05). Dosing varied widely by centre. Adjusting for age, there was no strong evidence that higher doses increased the chance of the next VL being <400 c/ml (OR = 
